# Stanford Accelerated Recovery Trial (START)

> **NCT01067144** · PHASE3 · TERMINATED · sponsor: **Stanford University** · enrollment: 422 (actual)

## Conditions studied

- Pain
- Breast Cancer
- Lung Cancer

## Interventions

- **DRUG:** Gabapentin
- **DRUG:** Lorazepam (active control)
- **DRUG:** Placebo (inactive)

## Key facts

- **NCT ID:** NCT01067144
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 422 (ACTUAL)
- **Why stopped:** Trial met futility stopping point
- **Last updated:** 2022-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01067144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01067144, "Stanford Accelerated Recovery Trial (START)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01067144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*